Clinical trials: Schizo-affective Disorder
Schizophrenia, Schizo Affective Disorder
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
- Trial name
- NCT03860597
- Testing
- Memantine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Glucose and Lipid Metabolism on Antipsychotic Medication
This project aims to a) evaluate the effects of selected antipsychotic medications on insulin action in skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue (whole-body lipolysis), b) evaluate the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
- Trial name
- Glulipid (NCT00515723)
- Testing
- risperidone, olanzapine, quetiapine
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Schizophrenia, Schizoaffective Disorder
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
This is a study comparing the benefits of two types of individual psychotherapy (cognitive-behavioral therapy for psychosis and supportive therapy) in symptomatic Veteran outpatients diagnosed with schizophrenia or…
- Trial name
- NCT00688259
- Testing
- Supportive Therapy (ST), Cognitive Behavioral Therapy for Psychosis (CBTp)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the newer antipsychotics are risk factors for development of diabetes.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00538642
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
Salsalate as an Adjunctive Treatment for Patients With Schizophrenia
This is a 12-week, open-label trial of salsalate 3 g/day as an adjunctive treatment in 15 schizophrenia subjects to examine salsalate's effect on psychopathology, cognitive functioning, and metabolic parameters.
- Trial name
- NCT01578486
- Testing
- salsalate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia, Schizo Affective Disorder
The Efficacy of Neural Stimulation in Individuals With Schizophrenia
The purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders.
- Trial name
- NCT05746494
- Testing
- tDCS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas at Dallas
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment in Patients With Early Psychosis
Cannabidiol (CBD) is a component of herbal cannabis that is present in varying concentrations in cannabis extracts. CBD has been shown to produce central effects including hypnotic, anticonvulsive, anxiolytic and neuroprotective…
- Trial name
- CBD (NCT02504151)
- Testing
- Cannabidiol
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation
The purpose of this study is to show that amantadine might help to reduce the side effect of the medications which are prescribed to treat schizophrenia or schizoaffective disorder.
- Trial name
- NCT00975611
- Testing
- Amantadine Hydrochloride, USP
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- David C. Henderson, MD
Schizophrenia, Schizo Affective Disorder
D-serine Augmentation of Neuroplasticity
Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired…
- Trial name
- NCT03711500
- Testing
- D-serine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Sodium Nitroprusside in Early Course Schizophrenia
Peripheral inflammation and microvascular dysfunction are central to the pathophysiology of schizophrenia (SZ). Retinal imaging allows for the accurate quantitative assessment of the condition of retinal microvessels, and early…
- Trial name
- NCT04986072
- Testing
- Sodium Nitroprusside, 5% Dextrose solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Beth Israel Deaconess Medical Center
Tobacco Use, Tobacco Smoking
Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)
Due to the pandemic, this study was modified from a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention to a feasibility and acceptability test of our…
- Conditions
- Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Tobacco Use Disorder
- Trial name
- PTSC-S (NCT03873337)
- Testing
- Persistence Targeted Smoking Cessation in SMI (PTSC-S), Nicotine patch
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Rutgers, The State University of New Jersey
Schizophrenia, Schizoaffective Disorder
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
The major objective of this proposal is to test the hypothesis that the addition of divalproex sodium to an atypical antipsychotic drug other than clozapine will significantly improve: a) cognition; and b) psychopathology…
- Trial name
- NCT00306475
- Testing
- Divalproex Sodium Extended-Release Tablets
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
Oxytocin and CBSST for People With Schizophrenia
A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others, which may reflect social aversion secondary to defeatist beliefs; decreased motivation for social…
- Trial name
- NCT01752712
- Testing
- CBSST + Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Improving Accessibility and Personalization of CR for Schizophrenia
This project will explore adaptations of treatments for schizophrenia, with the goal of optimizing their effectiveness in real-world clinical settings and readiness for broad deployment.
- Trial name
- NCT03576976
- Testing
- Cognitive Remediation
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse
- Trial name
- NCT00156715
- Testing
- Quetiapine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
The study attempts to evaluate a histamine analog long used for the treatment of Meniere's disease, betahistine, that shows promise in reversing the antihistaminergic effects thought to be involved in antipsychotic induced weight…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder
- Trial name
- NCT00709202
- Testing
- Betahistine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
- Trial name
- NCT03669640
- Testing
- RO6889450
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Dual Diagnosis
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
Many individuals with schizophrenia also suffer from marijuana addiction. Clozapine, an atypical antipsychotic medication, may prove useful at preventing drug relapse in schizophrenic individuals who are seeking treatment for…
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00498550
- Testing
- Clozapine, Treatment as usual
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dartmouth-Hitchcock Medical Center